Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Cohort Study for the UK.

Health Technology Assessment- United Kingdom

doi 10.3310/hta16060

Full Text

Abstract

Available in

Date

Authors

Publisher

National Institute for Health Research

Related search

Intravitreal Bevacizumab vs Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration

Archives of Ophthalmology
2007English

Ranibizumab Versus Verteporfin for Neovascular Age-Related Macular Degeneration

New England Journal of Medicine
Medicine
2006English

Photodynamic Therapy for Age-Related Macular Degeneration

The Review of Laser Engineering
2005English

Aflibercept for Neovascular Age-Related Macular Degeneration

Cochrane Database of Systematic Reviews
2016Norwegian Bokmål

Single-Session Photodynamic Therapy Combined With Intravitreal Bevacizumab and Triamcinolone for Neovascular Age-Related Macular Degeneration

BMC Ophthalmology
MedicineOphthalmology
2007English

Macular Atrophy in Neovascular Age Related Macular Degeneration

Journal of Clinical Review & Case Reports
2019English

Impact of Lesion Size on Photodynamic Therapy With Verteporfin of Predominantly Classic Lesions in Age Related Macular Degeneration

British Journal of Ophthalmology
Molecular NeuroscienceOphthalmologySensory SystemsCellular
2005English

A Retrospective Study of the Real-Life Utilization and Effectiveness of Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration In the UK

Clinical Ophthalmology
Ophthalmology
2016English

Comparative Study of Photodynamic Therapy Monotherapy Versus Triplemanagement in Age-Related Macular Degeneration

Turkish Journal of Medical Sciences
Medicine
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy